Ohio State Navbar

News


Meet John Byrd: A beacon of hope for cancer patients


August 29, 2016

Dr. John Byrd is recognized internationally for his pioneering work in developing highly effective treatments for patients suffering from the most common form of leukemia. Byrd, director of Ohio State’s Division of Hematology, now holds Ohio State’s most prestigious award for select faculty members who have exceptional accomplishments in research, teaching and service. Byrd discusses the life-saving research occurring at Ohio State in this second installment of a three-part series highlighting 2016 Distinguished University Professors The rest of the story



WORKSHOP SLATED ON EXTRACELLULAR VESICLES IN CANCER BIOLOGY


May 05, 2016

Experts from the OSUCCC – James and outside institutions will speak at a free Workshop on Extracellular Vesicles in Cancer Biology from 8:30 a.m.-4:30 p.m. Friday, May 27, in L035 James (Wasserstrom Family Conference Room). Breakfast and lunch will be provided. View agenda Directors for the workshop are Ramiro Garzon, MD, associate professor in the Division of Hematology at Ohio State and member of the Leukemia Research Program at the OSUCCC – James, and Muller Fabbri, MD, PhD, assistant professor in the Children's Center for Cancer and Blood Diseases at the University of Southern California. The workshop will enable scientists performing or planning to perform exosome and microvesicle research to meet, exchange ideas, discuss biological implications and future directions, and point out current problems and controversies in techniques, definitions and characterizations. Register The rest of the story



Byrd Chosen A Distinguished University Professor


May 04, 2016

The university has named John Byrd, MD, director of the Division of Hematology in the Department of Internal Medicine, a 2016 Distinguished University Professor. Dr. Byrd holds The D. Warren Brown Designated Chair in Leukemia Research. Distinguished University Professor is the highest honor the university bestows on a faculty member. To date, only 53 other faculty members have held the Distinguished University Professor title. The rest of the story



Ohio State's 2016 ASH Review Set for Jan. 22


December 08, 2015

Registration is open for Ohio State’s 2016 ASH Review, a Jan. 22 event that will provide a comprehensive overlook at advances in the biology, etiology, diagnosis, therapy and evidence-based management of blood cancers as presented at the 57th American Society of Hematology (ASH) Annual Meeting & Exposition held in December 2015 in Orlando, Fla. The ASH Review, to be held from 7:30 a.m.-3:30 p.m. in Room 115 of Ohio State’s Biomedical Research Tower, will include a presentation of the Michael R. Grever, MD, Distinguished Professor Lectureship by John C. Byrd, MD, professor and director of the Division of Hematology at Ohio State, and co-leader of the Leukemia Research Program at the OSUCCC – James. There is no fee to attend the review, and CME credit is available. Questions? Contact sarah.schmidt@osumc.edu or call 293-5521. The rest of the story



Immunology Seminar Program


November 10, 2015

NOV. 17 – Jianhua Yu, PhD, Associate Professor, Division of Hematology, Department of Internal Medicine at Ohio State, and Member of the Molecular Carcinogenesis and Chemoprevention Program at the OSUCCC – James, “Understanding NK Cell Biology and Driving and Mobilizing Immune Cells to Kill Tumor Cells” The rest of the story



Caligiuri Delivers 'State of the Cancer Program Address'


November 10, 2015

OSUCCC – JAMES IS CHANGING THE LANDSCAPE OF CANCER CARE Continuing growth and advancement during the past year have bolstered Ohio State’s capacity for changing the landscape of cancer care and research in Ohio and around the globe, OSUCCC Director and James CEO Michael A. Caligiuri, MD, said Monday. Delivering his “State of the Cancer Program Address,” Caligiuri referenced “an amazing year” that included the opening of a new James Cancer Hospital and Solove Research Institute, and the attainment of a perfect score following a National Cancer Institute (NCI) five-year site review that led to a second consecutive “exceptional” rating for the OSUCCC – James, assuring its re-designation as a comprehensive cancer center. “If you take anything away from here today, it should be that we’ve had extraordinary growth and improvement in everything we do, and it’s making a profound difference to people who hear those three words, ‘You have cancer,’” Caligiuri told a standing-room-only audience in OSU’s Biomedical Research Tower. The rest of the story



John C. Byrd, MD Received the Hendrix College Odyssey Medal for Research


November 10, 2015

John C. Byrd, MD, professor and director of the Division of Hematology at Ohio State, where he also is co-leader of the Leukemia Research Program at the OSUCCC – James, received the Hendrix College Odyssey Medal for Research on Oct. 22 in Conway, Ark. Hendrix, a private liberal arts college where Byrd earned his undergraduate degree with distinction in chemistry in 1987, presents the Odyssey Medal each year to alumni “whose personal and professional achievements exemplify the values of engaged liberal arts and science education.” Byrd was among four recipients this year, and the only one for Research; the others were awarded for Special Projects or Service to the World. The college states that Byrd, who also holds the D. Warren Brown Designated Chair in Leukemia Research at Ohio State, is “a nationally known researcher and clinical specialist in leukemia and other hematologic malignancies” who has “been part of the development of multiple acute myeloid leukemia and chronic lymphocytic leukemia therapeutics.” The rest of the story



Study Rejects Biologic Age As Limiting Factor For Stem Cell Transplants


November 10, 2015

STUDY REJECTS BIOLOGIC AGE AS LIMITING FACTOR FOR STEM CELL TRANSPLANTS More than 40 percent of older patients with acute myeloid leukemia (AML) can remain in long-term cancer remission through a modified, less aggressive approach to donor stem cell transplantation, according to the results of a phase II study led by oncologists at the OSUCCC – James. Steven Devine, MD, director of blood and marrow transplantation, led the study, which was published in the Journal of Clinical Oncology. The rest of the story



Jianhua Yu, PhD Presenting at Immunology Seminar Program 11/17 noon-1pm in 400 Prior Hall


October 02, 2015

Jianhua Yu, PhD, Associate Professor, Division of Hematology, Department of Internal Medicine at Ohio State, and Member of the Molecular Carcinogenesis and Chemoprevention Program at the OSUCCC – James, “Understanding NK Cell Biology and Driving and Mobilizing Immune Cells to Kill Tumor Cells” The rest of the story



Rosa Lapalombella, PhD Presenting Grand Rounds on 10/16, 8-9am in James L035


October 02, 2015

Rosa Lapalombella, PhD, assistant professor in Ohio State’s Department of Internal Medicine, Division of Hematology, and a member of the Leukemia Research Program at the OSUCCC – James, will present “PRMT5 Dysregulation as a Driver Event in Richter’s Transformation” at the Oct. 16 Grand Rounds. Dr. Lapalombella’s lecture will be the second one of two presented by recent American Cancer Society grant awardees from Ohio State. Her research interests include leukemia and lymphoma. Her work focuses on two major areas: epigenetic alterations of cancer cells, and development of experimental therapeutics for hematologic disease. Dr. Lapalombella earned her PhD in biological sciences at the University of Bologna in Italy and completed her postdoctoral research training at the OSUCCC – James. The rest of the story



Next